Pioglitazone - CAS 111025-46-8
Catalog number: B0084-081675
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C19H20N2O3S
Molecular Weight:
356.44
COA:
Inquire
Targets:
PPAR
Description:
Pioglitazone is a PPAR agonist that exhibits antidiabetic activity in patients with type 2 diabetes mellitus. It has no effect on type 1 diabetes.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-081675 5 g $248 In stock
B0084-081675 10 g $448 In stock
Bulk Inquiry
Purity:
>98%
Appearance:
White to Off-white Solid
Synonyms:
5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
MSDS:
Inquire
Melting Point:
171-174°C
InChIKey:
HYAFETHFCAUJAY-UHFFFAOYSA-N
InChI:
InChI=1S/C19H20N2O3S/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23)
Canonical SMILES:
CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3
1.Generalized intense pruritus during canagliflozin treatment: Is it an adverse drug reaction?
Vasapollo P, Cione E, Luciani F, Gallelli L1. Curr Drug Saf. 2016 Apr 5. [Epub ahead of print]
Selective agents able to locate and identify unique targets represent a crucial aspect of modern pharmacology. The exclusive location of sodium-glucose co-transporter-2 (SGLUT2) on kidneys prompt companies to develop SGLT2 inhibitors that today are the latest class of drugs for diabetes treatment. In particular, canagliflozin blocks the re-absorption of glucose in the kidney lowering blood glucose levels by increasing glucose excretion. We report a 61-year old woman who developed an intense and severe pruritus during the treatment with canagliflozin. Clinical and laboratory findings excluded the presence of systemic or skin diseases able to induce pruritus. The discontinuation of canagliflozin and the treatment with pioglitazone/metformin fixed combination induced a remission of pruritus. This case emphasizes the need to consider pruritus as a differential diagnosis during the treatment with canagliflozin.
2.Pioglitazone alleviates inflammation in diabetic mice fed a high-fat diet via inhibiting advanced glycation end product (AGE)-induced classical macrophage activation.
Jin X1,2, Liu L2, Zhou Z1,2, Ge J3, Yao T4, Shen C2. FEBS J. 2016 Apr 8. doi: 10.1111/febs.13735. [Epub ahead of print]
Classically activated macrophages (M1) are associated with inflammation in diabetic patients. Inflammation is a known risk factor in diabetes. This study tested the hypothesis that pioglitazone (PIO) alleviates inflammation in diabetic mice fed a high-fat diet by inhibiting advanced glycation end product (AGE)-induced classical macrophage activation. Indeed, we found that AGE treatment promoted transcription of pro-inflammatory molecules and M1 surface markers, but that PIO increased the expression of anti-inflammatory genes and decreased the expression of pro-inflammatory mediators in bone marrow derived macrophages (BMDMs) in a dose-dependent manner. Furthermore, pretreatment with PIO abrogated the effects of AGE on pro-inflammatory markers and partly inhibited AGE-induced NFκB activation. PIO treatment partly reduced the inflammatory phenotype in diabetic ApoE-/- mice, and significantly reduced NFκB activation in plaques. Therefore, we conclude that pioglitazone blocks classical activation of macrophages and attenuates inflammation in mouse models of diabetes.
3.EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: is universal screening appropriate?
Byrne CD1,2, Targher G3. Diabetologia. 2016 Apr 7. [Epub ahead of print]
Non-alcoholic fatty liver disease (NAFLD) is very common in people with type 2 diabetes and although estimates for the prevalence NAFLD vary according to age, obesity and ethnicity, some studies have indicated that up to 75% of patients with type 2 diabetes may be affected. During the last 15 years there has been a vast amount of research into understanding the natural history, aetiology and pathogenesis of NAFLD; and now there is a better understanding of the strengths and limitations of diagnostic tests for NAFLD, the influence of lifestyle changes and the effects of potential treatments. With this advance in knowledge, it is apposite that a number of organisations have started to develop guidelines for the diagnosis and management of NAFLD. Given the high proportion of patients with type 2 diabetes who are affected by this liver condition, it is now important to consider how any guideline will affect the care, diagnosis and treatment of patients with type 2 diabetes.
4.Suppression of connective tissue growth factor mediates the renoprotective effect of Sitagliptin rather than Pioglitazone in type 2 diabetes mellitus.
Ali SM1, Khalifa H2, Mostafa DK3, El Sharkawy A1. Life Sci. 2016 Apr 3. pii: S0024-3205(16)30192-8. doi: 10.1016/j.lfs.2016.03.043. [Epub ahead of print]
AIM: Diabetic nephropathy (DN) is a leading cause of end-stage renal disease, and thus, the ability of antidiabetic drugs to ameliorate renal microvascular disease may be as important as their ability to control blood glucose. Therefore, we investigated the reno-protective effect of the antidiabetic drugs, Sitagliptin and Pioglitazone, versus combined Metformin/Enalapril in a rat model of type 2 diabetes.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related PPAR Products


CAS 810677-36-2 PPARα-MO-1

PPARα-MO-1
(CAS: 810677-36-2)

A potent PPARα modulator

CAS 50892-23-4 Pirinixic Acid

Pirinixic Acid
(CAS: 50892-23-4)

WY 14643 (Pirinixic Acid) is a potent peroxisome proliferator and activator of PPARα with EC50 of 1.5 μM.

CS-7017 monohydrate
(CAS: 1048002-36-3)

CS-7017 monohydrate is a peroxisome proliferator activated receptor gamma (PPAR) agonist. It is a potential therapy for thyroid cancer and liposarcoma. It is al...

CAS 25812-30-0 Gemfibrozil

Gemfibrozil
(CAS: 25812-30-0)

Gemfibrozil is the generic name for an oral drug used to lower lipid levels. It belongs to a group of drugs known as fibrates. It is most commonly sold as the b...

CAS 41859-67-0 Bezafibrate

Bezafibrate
(CAS: 41859-67-0)

Bezafibrate (marketed as Bezalip and various other brand names) is a fibrate drug used for the treatment of hyperlipidaemia. It helps to lower LDL cholesterol a...

CAS 637-07-0 Clofibrate

Clofibrate
(CAS: 637-07-0)

Clofibrate is a fibric acid derivative used in the treatment of hyperlipoproteinemia type III and severe hypertriglyceridemia.

PT-S58
(CAS: 1356497-92-1)

PT-S58 is a full peroxisome proliferator-activated receptor (PPAR) β/δ antagonist as a derivative of GSK0660. But PT-S58 has a three-fold higher affinity for th...

CAS 622402-22-6 GW-590735

GW-590735
(CAS: 622402-22-6)

GW-590735 is a potent and selective agonist of PPARα. Its EC50 value is 4 nM for the expression a GAL4-responsive reporter gene and at least 500-fold selectivit...

Chemical Structure

CAS 111025-46-8 Pioglitazone

Quick Inquiry

Verification code

Featured Items